Podcasts about abbv

It hasn't been in many headlines (thanks, AI), but pharmaceutical companies are on a merger & acquisition spree that could break records. With more than $126 billion in deals so far this year, companies are looking for novel drug canddiates and clinical stage companies to bolster their own development pipeline. We'll take a dive into what's driving this M&A frenzy and what companies look interesting in the pharmaceutical space today.Tyler Crowe, Matt Frankel, and Lou Whiteman discuss:- Big Pharma using big wallets for M&A- Who's at risk of running off a patent cliff- Regulatory changes adding fuel to the fire- Companies doing great for patients (and investors)- Mailbag: Is Pfizer ok? Companies discussed: LLY, MRK, UTHR, ASND, PFE, ABBV, GSK, NVO, RHHBYHost: Tyler CroweGuests: Matt Frankel, Lou WhitemanEngineer: Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Whiplash hits geopolitical headwinds as a back-and-forth in U.S. and Iran talks fluctuate the price action in futures. Tom White explains why investors should take headlines out of Iran "with a grain of salt" as peace talks to fully reopen the Strait of Hormuz continue. In equities, Tom talks about the price target hikes in AI semiconductor equipment makers and AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE). He also touches on reports of SpaceX (SPCX) preparing a $20 billion offering. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Micron (MU) is entering a new strategic partnership with Anthropic as Needham raises its price target on the AI memory stock. Credo Technology (CRDO) gets a new bull in Evercore ISI after it initiated an outperform rating. AbbVie (ABBV) aims to acquire Apogee Therapeutics (APGE) for $10.9 billion. Diane King Hall highlights the top moving stocks into Monday's trading session. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

SpaceX and OpenAI are heading for the public markets with combined valuations approaching 3 trillion dollars; but by the time retail investors get access, has the real opportunity already passed? We will break down the IPO cycle most investors don't understand, why hype distorts valuation, and the five things you should watch before buying into any mega-IPO.Today's Stocks & Topics: Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (TLK), Market Wrap, VICI Properties Inc. (VICI), Top 5 Technical Indicators, The Mega IPO Setup: What SpaceX and OpenAI Really Mean for Your Money, AstraZeneca PLC (AZN), AbbVie Inc. (ABBV), Sunbelt Rentals Holdings, Inc. (SUNB), Roth vs. Traditional I-R-S.*Correction: In this episode, we incorrectly stated that Robinhood was worth $2 billion. At the time of airing, Robinhood's market capitalization was approximately $75 billion.Our Sponsors:* Check out Anthropic: https://claude.ai/invest* Check out Pebl: https://hipebl.ai* Check out Plaud AI and use my code INVEST for a great deal: https://plaud.ai* Check out Quince: https://quince.com/invest* Check out TruDiagnostic and use my code INVEST20 for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Wholesale prices rose sharply in the latest report, pointing to persistent inflation that could complicate Federal Reserve policy decisions. This unexpected uptick in producer prices suggests the inflation fight is far from over, despite earlier optimism about cooling price pressures.Today's Stocks & Topics: Hertz Global Holdings, Inc. (HTZ), Market Wrap, Ball Corporation (BALL), KPP Newsletter, Inflation's Stubborn Return: Wholesale Prices Surge Signals Persistent Price Pressures, Whirlpool Corporation (WHR), Key Benchmark Numbers: Treasury Yields, Gold, Silver, Oil and Gasoline, ADMA Biologics, Inc. (ADMA), Jobs Report, Nucor Corporation (NUE), AbbVie Inc. (ABBV).Our Sponsors:* Check out Anthropic: https://claude.ai/invest* Check out Pebl: https://hipebl.ai* Check out Progressive: https://progressive.com* Check out Quince: https://quince.com/INVESTAdvertising Inquiries: https://redcircle.com/brands

Max Wasserman is still bullish and anticipates more volatility ahead – which creates opportunities to buy. He likes Alphabet (GOOGL), Broadcom (AVGO), and other megacaps but thinks valuations are “much more compelling” in the other 493 in the S&P 500. He likes pharmaceuticals like AbbVie (ABBV) and Bristol-Myers Squibb (BMY), especially with their dividends. He's bullish on Home Depot (HD) as the Fed cuts rates (even as he thinks they shouldn't), and the defense sector. Another pick is Waste Management (WM). ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Our 52nd and final show of 2025, thanks for listening, Happy New Year!We talk about the top stocks to own for 2026, including top dividend payers.  We also discuss the upcoming 2026 IPO of Elon Musk's SpaceX, and how you might participate right now.

Don Nesbitt looks ahead to the Fed press conference this week and to 4Q earnings season, which begins in about a month. He's also noticing rotation within the market out of big tech. His stock picks include AbbVie (ABBV), as he likes healthcare overall and thinks it has good growth prospects. Another is Medtronic (MDT), which has a “well established moat” and “good earnings visibility.” Microsoft (MSFT) “had a stellar report,” and he sees further upside.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

We will discuss how falling birth-rates are becoming more than just a social issue because they are intertwined with economic systems and capitalist assumptions. Today's Stocks & Topics: The Campbell's Company (CPB), Market Wrap, Babies, Capitalism & a Demographic Crossroads, Alexandria Real Estate Equities, Inc. (ARE), Panasonic Holdings Corporation (PCRHY), A-I might replace Junior Bankers, Gold and Uranium Sectors, AbbVie Inc. (ABBV), Vertex Pharmaceuticals Incorporated (VRTX), A-I Financial Models.Our Sponsors:* Check out Gusto: https://gusto.com/investtalk* Check out Progressive: https://www.progressive.com* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

Arthur Wong examines AbbVie (ABBV) following the healthcare company's earnings beat in its 3Q. He discusses the pharmaceutical pipeline, its oncology segment and current offerings like its autoimmune medication Humira. Arthur discusses the relationship between weaker consumer sentiment and patients willingness to spend on expensive medical treatments. He also talks about the industry trend to negotiate lower drug-costs with the Trump administration. He says tariffs and "MFN" Pricing (Most Favored Nation) are the biggest headwinds for pharmaceutical companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

S&P Futures are pointing lower this morning as investors digest a wave of earnings, Fed commentary, and geopolitical updates. Mega-cap tech continues to deliver strong margins, though Microsoft's softer PC outlook weighed on its guidance. Fed Chair Jerome Powell struck a hawkish tone in yesterday's press conference, signaling that a December rate cut is not a foregone conclusion. Meanwhile, U.S.–China talks wrapped up as expected, easing trade tensions with no surprises. We'll also touch on YouTube's expiring agreement with Disney, the FDA's push to streamline biologic drug testing, and the latest corporate movers — from GOOG and LLY to META, MSFT, and MRK. After the bell, all eyes turn to Apple, Amazon, Coinbase, Reddit, and Roku, with ABBV, CVX, and XOM set to report tomorrow morning.

3Q earnings season is looking “pretty good” so far, says Don Nesbitt. He notes that analysts have been revising their estimates upwards for “the first time in about four years.” He likes AbbVie (ABBV), which he expects to beat earnings next week, PNC Financial (PNC), where he sees a “great buying opportunity” after they fell on earnings, and Linde (LIN), a “leader in the gas area” that is critical for industrial expansion.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

David Darst looks at the potential Fed Chair nominees and why he thinks Scott Bessent wouldn't take the position. He looks at historical rate cutting cycles and “fever and fervor” in the markets, particularly in AI. He expects earnings to be a market driver next year. David examines his stock picks from March, including GOLD, EL, and ABBV, and brings some new names: Verizon (VZ), Pfizer (PFE), and a gold miner ETF (GLD).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Some drug stocks are cheap but is it another fake out? (0:30) - Can You Find Strong Value Investments In Drug Stocks Right Now? (3:40) - Breaking Down The Recent Industry Performance (9:00) - Tracey's Top Stock Picks (30:00) - Episode Roundup:  PFE, MRK, ABBV, LLY, NVO

Some drug stocks are cheap but is it another fake out? (0:30) - Can You Find Strong Value Investments In Drug Stocks Right Now? (3:40) - Breaking Down The Recent Industry Performance (9:00) - Tracey's Top Stock Picks (30:00) - Episode Roundup:  PFE, MRK, ABBV, LLY, NVO Podcast@Zacks.com

Starting in 2026, workers aged 50 and older who earned over $145,000 in the prior year will be required to make their 401(k) catch-up contributions on an after-tax Roth basis (a key tax shift mandated by the SECURE 2.0 Act). Today's Stocks & Topics: Trane Technologies plc (TT), Circle Internet Group (CRCL), Market Wrap, Roth or Bust: The $145K 401(k) Catch-Up Rule Change for 2026, Schlumberger Limited (SLB), Zebra Technologies Corporation (ZBRA), Alternative Investments, AbbVie Inc. (ABBV), Gold.Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

This week on Dividend Talk, Derek is joined by Jeremy from Dividend Stockpile to explore some of the biggest Megatrends shaping our investing future. We cover the opportunities and risks in infrastructure, clean energy, technology, and healthcare, and how dividend investors can position themselves for the next decade and beyond.You'll hear about recent dividend news from Interface (TILE) and Agree Realty (ADC), how US and European infrastructure approaches differ, why utilities like Iberdrola (IBE.MC) and Enel (ENEL.MI) stand out, and how tech giants Meta (META), Alphabet (GOOG), and Microsoft (MSFT) fit into the AI megatrend. We also look into healthcare innovation, options income strategies, and favourite finance content creators.Tickers Mentioned: TILE, ADC, O, BAM, BIP, NEE, DUK, ED, IBE.MC, ENEL.MI, ABB, DG.PA, META, GOOG, MSFT, GE, CWEN, ASML.AS, SAP, MDT, MRK, ABBV, NVO, LLY, ROG.SW, SNY, SYK, ABT, BDX, RMD, STRCChapters:00:00 – Introduction & Guest Welcome02:52 – Company News: Interface & Dividend Increases05:41 – Agree Realty & REIT Quality08:43 – Understanding Megatrends11:51 – Infrastructure as a Megatrend29:06 – Clean Energy Transition39:31 – The Rise of Technology & AI46:51 – Healthcare Opportunities01:04:06 – Options Income Strategies & High Yield Ideas01:20:06 – Favorite Finance Content Creators & Closing RemarksGet a free sample of our premium dividend newsletter! Stay ahead of the market with in-depth stock analysis here: https://dividendtalk.eu/download-your-free-samples/ Stay Updated:Twitter - @DividendTalk_Twitter - @European_DGIJoin our Facebook Community - Dividend Talk Facebook GroupJoin our Discord group - https://discord.gg/nJyt9KWAB5

In this week's episode of Dividend Talk, we kick off with our Q2 performance review , looking at how our dividend portfolios fared, what we bought, sold, and learned over the past quarter.  We also dive into three big names making headlines: Wolters Kluwer's sharp share price drop and the fear of AI disruption, Novo Nordisk's earnings and competition with Eli Lilly, and UnitedHealth's reduced outlook.  Along the way, we cover dividend hikes and cuts from around the globe, have some laughs over corporate slogans, and answer a packed list of listener questions ranging from sector risks to portfolio construction. SEE YOU ON THE INSIDE!! Tickers discussed: WKL.AS, NVO, LLY, UNH, HEIA.AS, NN.AS, AD.AS, ITW, CLX, AWR, WHR, LGEN.L, MRK, LVMH.PA, TGT, LYB, NKE,CVX, HPQ, MSFT, SHEL, BTI, BAM, BAES.L, HORNB.BR, UPS, PEP, CCOI, ORA.PA,ASR.AS, ASML.AS, UL, GLB.IR, KRZ.F, KESKOB.HE, KNEBV.HE, SAMPO.HE, AGE.BR, XIOR.BR,ASC.BR, SHL.DE, DEF.F, NVO-B.CO, VICI, RY, DOL.TO, FTS.TO, UKW.L, VOLVB.ST,INVE-A.ST, INVE-B.ST, SEB-A.ST, SWED-A.ST, HAND-B.ST, SHELL.AS, VIE.PA, O,SECUB.ST, ABBV, BAYN.DE.  Join us :[Facebook]  - Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    ,  @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Premium Services] - https://dividendtalk.eu/how-it-works

Mike Shorr walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a call spread. Later, he also looks at Vertiv (VRT) which he believes is set up for a hull reversion entry. Kevin Green looks at the bullish and bearish technical patterns on each of the stock charts.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Don Nesbitt is looking for “quality stocks with good earnings.” He sees strength right now in Honeywell (HON), AbbVie (ABBV), and T-Mobile (TMUS). He warns that the top ten companies have to see decent earnings growth to keep markets up, but the other 490 also need to perform well to create market breadth. He considers the market to be in “late cycle expansion.”======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

12 Articles With Great ESG Stock Picks. Includes the terrific Humankind ranking, top infrastructure, lithium mining, and AI stock picks. By Ron Robins, MBA Transcript & Links, Episode 157, July 25, 2025 Hello, Ron Robins here. Welcome to my podcast episode 157, published on July 25, 2025, titled “12 Articles With Great ESG Stock Picks.” Before I begin, I want to let you know that my next podcast will be on August 22nd as I'm taking some time off. So, this podcast is presented by Investing for the Soul. Investingforthesoul.com is your go-to site for vital global, ethical, and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content, including stock symbols and bonus material, on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. Additionally, please visit this podcast's webpage for links to the articles and additional company and stock information. I have a great crop of 12 articles for you in this podcast! Note that some companies are mentioned more than once! ------------------------------------------------------------- Humankind 100 rankings I'm beginning this episode with another of my favourite company rankings whose annual list has just been released. It's the Humankind 100 rankings. Here is an overview of them from their website. “The Humankind 100 celebrates the one hundred U.S. public companies with the highest Humankind Values. We believe these companies consistently work to create large amounts of value, not just for their investors, but for humanity at large. The Humankind 100 companies are ranked based on Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large, and are therefore among the most ethical companies in the United States, according to our research.” End quotes. Their top 5 companies are Alphabet Inc. (GOOGL), Eli Lilly & Company (1LLY.MI), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Pfizer Inc. (PFE). ------------------------------------------------------------- Infrastructure Stocks To Consider - July 12th This second article features a sector favoured by many ethical and sustainable investors. The article is titled Infrastructure Stocks To Consider - July 12th. It's by MarketBeat and seen on marketbeat.com. Here are some quotes from the article. “1. NVIDIA Corporation (NASDAQ:NVDA) provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. 2. Coinbase Global, Inc. (NASDAQ:COIN) provides financial infrastructure and technology for the crypto economy in the United States and internationally. The company offers the primary financial account in the crypto economy for consumers; and a marketplace with a pool of liquidity for transacting in crypto assets for institutions. Read Our Latest Research Report on COIN 3. Alphabet (NASDAQ:GOOGL) offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. Read Our Latest Research Report on GOOGL 4. Broadcom (NASDAQ:AVGO) designs, develops, and supplies various semiconductor devices with a focus on complex digital and mixed signal complementary metal oxide semiconductor based devices and analog III-V based products worldwide. Read Our Latest Research Report on AVGO 5. Oracle (ORCL) offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing.” End quotes. ------------------------------------------------------------- Best Lithium Mining Stocks 2025: Buy Top Mining Stocks Now Every investor knows that lithium is a basic mineral for electric batteries. So, this next article will interest many investors. It's titled Best Lithium Mining Stocks 2025: Buy Top Mining Stocks Now. It's by Farmonaut and found on farmonaut.com. Here are some quotes by Farmonaut on each of their picks. “1. Albemarle Corporation (NYSE: ALB) headquartered in the USA, is the world's largest lithium producer… With operations spanning North America, South America, and Australia, Albemarle boasts: Diversified extraction & processing operations, including high-margin lithium brine and hard rock mining projects Ongoing investments to expand production capacity in Nevada (USA), Chile, and Australia A resilient supply chain and ability to scale output to meet global demand Strategic partnerships with leading EV battery makers Strong commitment to sustainable mining and ESG practices Albemarle's scale, geographic diversification, and innovation position it as one of the best performing mining stocks of 2025. 2. Sociedad Química y Minera de Chile (or SQM) (NYSE: SQM) is South America's lithium market leader. Based in Santiago, Chile, SQM boasts some of the world's largest and lowest-cost lithium brine operations situated in the renowned Lithium Triangle (Chile, Argentina, Bolivia): Extensive lithium reserves & robust extraction technology, delivering high efficiency Geopolitical stability—Chile enjoys a relatively favorable mining regulatory environment compared to other regions Cost-effective production enables SQM to remain highly profitable even as competition heats up Continuous expansion to satisfy increasing global lithium demand for EV batteries and storage solutions Environmental sustainability programs, making SQM attractive for ESG-focused investors SQM competitive positioning ensures it remains a top choice in the best lithium mining stocks to buy for 2025. 3. Livent Corporation (NYSE: LTHM) distinguishes itself by focusing on high-purity lithium chemicals for next-generation battery technologies. With operations in the United States, Argentina, and China, Livent stands out for: Supplying premium lithium hydroxide and carbonate solutions for advanced battery manufacturers Strong partnerships with key players in the EV battery chain, including Tesla Expansion projects in Argentina and the U.S., boosting 2025 production capacity and flexibility ESG and sustainability initiatives for responsible lithium extraction Livent is uniquely positioned for specialty market growth, making it one of the best lithium mining stocks for investors eyeing niche applications and supply chain integration. 4. Piedmont Lithium (NASDAQ: PLL) though a smaller player, it has become a rising star by focusing on high-quality spodumene reserves in the United States—especially in North Carolina's Carolina Tin-Spodumene Belt. Piedmont brings: Strategic U.S. supply source—critical for domestic battery manufacturers and government-led supply chain diversification Fast-tracked expansion projects supported by U.S. regulatory incentives and EV adoption targets Potential to benefit from blockchain-based traceability in mining—enhancing transparency for institutional investors Growing interest from global automakers and battery companies seeking secure lithium supply Piedmont's agility and domestic positioning could mean outsized growth as U.S. policy emphasizes onshoring critical battery mineral chains.” End quotes. ------------------------------------------------------------- 5 Artificial Intelligence (AI) Infrastructure Stocks Powering the Next Wave of Innovations Now, like most investors, you probably are invested in AI stocks, either directly or via funds. Hence, this next article 5 Artificial Intelligence (AI) Infrastructure Stocks Powering the Next Wave of Innovations, should interest you. It's by Justin Pope and found on fool.com. Here is some of what Mr. Pope says about his picks. “1. Nvidia (NASDAQ: NVDA) The company has maintained its winning position as it progressed from its previous Hopper architecture to its current Blackwell chips, and it expects to launch its next-generation architecture, with a CPU called Vera and a GPU called Rubin, next year. Analysts expect Nvidia's revenue to grow to $200 billion this year and $251 billion in 2026.  2. Amazon (AMZN) Web Services (AWS) has long been the world's leading cloud platform, with about 30% of the cloud infrastructure market today. Through the cloud, companies can access and deploy AI agents, models, and other software throughout their businesses. 3. Microsoft (MSFT) Its Azure is the world's second-largest cloud platform, with a market share of approximately 21%. Microsoft stands out from the pack for its deep ties with millions of corporate clients. 4. Arista Networks (ANET) sells high-end networking switches and software that help accomplish this. The company has already thrived in this golden age of data centers, with top clients including Microsoft and Meta Platforms, which happen to also be among the highest spenders on AI infrastructure. 5. Broadcom (AVGO) which specializes in designing semiconductors used for networking applications. For example, Arista Networks utilizes Broadcom's Tomahawk and Jericho silicon in the networking switches it builds for data centers. Broadcom's AI-related semiconductor sales increased by 46% year-over-year in the second quarter.” End quotes. ------------------------------------------------------------- Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) The final reviewed article for this podcast episode is titled Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) and was written by the Analyst Team and seen on asktraders.com. Now a few quotes from the article by the Team. “1. Ecolab (ECL) a global leader in water, hygiene, and infection prevention solutions, presents a straightforward ethical narrative. Its products and services help businesses reduce water consumption, improve hygiene standards, and prevent infections, contributing directly to public health and environmental protection… Analyst ratings remain in line with current pricing, with Wells Fargo & Company reiterating a price target of $260.00 in May 2025. With the Ecolab stock price having gained 14% since the start of the year, the company has managed to outperform the market on the period whilst holding true to it's ethical standing. While its dividend yield of approximately 1.1% is slightly higher than others on the list, its P/E ratio of around 38x indicates a similar valuation based on future earnings potential. 2. Microsoft (MSFT) presents a complex ethical profile. On one hand, its commitment to carbon neutrality, investments in renewable energy, and initiatives to bridge the digital divide are commendable… The stock's impressive 20% YTD return and a consensus analyst price target of $475 reflect market confidence in its financial stability and future growth, primarily driven by its cloud and AI segments, making it one to keep on shortlists… While Microsoft offers a modest dividend yield of around 0.7%, its high P/E ratio of approximately 36x suggests a premium valuation reflecting its growth potential rather than a focus on immediate shareholder returns. The company's low debt-to-equity ratio underscores its financial strength, allowing it to invest heavily in research and development and pursue ambitious sustainability goals. 3. United Natural Foods (UNFI) stock has pulled back ~15% this year, although remains firmly higher over the past 12 months, with a gain of more than 70%. The company, a leading distributor of natural, organic, and specialty foods, presents the most challenging investment case with the recent cyber incident causing a sharp pullback in the stock. This could in fact be an opportunity… Unlike Microsoft and Ecolab, United Natural Foods does not offer a dividend, reflecting its current financial constraints. Its low P/E ratio of around 8x suggests a deeply discounted valuation, reflecting the market's skepticism about its turnaround prospects. Recent earnings on July 16 beat expectations, however, and the stock is on the move with an 8% gain immediately off the back.” End quotes. ------------------------------------------------------------- More articles of interest from around the world for ethical and sustainable investors 1. Title: Top 10: Wind Power Companies on energydigital.com. By Jasmin Jessen. 2. Title: Ethical Companies To Invest In 2025 (ECL, MSFT, UNFI) on AskTraders.com. By Analyst Team. 3. Title: The Green Gold Rush: Why Techem's $6.7B Sale Signals a Buying Opportunity on ainvest.com. By Wesley Park. 4. Title: AJ Bell adds Rathbone Ethical Bond to buy list on portfolio-advisor.com. By Christian Mayes. 5. Title: Procter & Gamble Named Top Socially Responsible Dividend Stock on ainvest.com. By Ainvest. 6. Title: 11 Best Halal Dividend Stocks to Buy Now on insidermonkey.com. By Vardah Gill. 7. Title: JPMorgan Picks 3 Top Stocks In Alternative Energy On Heels Of Trump's 'Big Beautiful Bill' - First Solar (NASDAQ:FSLR), Brookfield Renewable (NYSE:BEPC), and HASI (NYSE:HASI) on benzinga.com. By Priya Nigam. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast, “12 Articles With Great ESG Stock Picks.” Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these deeply troubled times! Contact me if you have any questions. Thank you for listening. As I mentioned earlier, I'm taking some time off, so I'll talk to you next on August 22nd. Bye for now.   © 2025 Ron Robins, Investing for the Soul

In this episode of Dividend Talk, we dive into the drama at UnitedHealth Group (UNH) from earnings disappointments to fraud allegations and a sudden CEO exit. Is it a buying opportunity or a classic falling knife?We also break down strong earnings from two European giants: Siemens (SIE.DE) and Allianz (ALV.DE). Both companies delivered rock-solid results, reminding us why Europe is a fertile ground for dividend growth investors.Along the way, we reflect on what we'd do differently if we started our investing journeys today, why conviction matters more than share price, and whether preferred stocks or spin-offs like Magnum are worth a look.

David Kaplan says AbbVie (ABBV) shows "unusually strong growth compared to peers." While he notes parts of its business is exposed to tariffs, the pharmaceutical and medical device industries are typically resilient to macro headwinds, and he believes AbbVie can withstand most. George Tsilis later joins to offer example options trades in AbbVie and UnitedHealth (UNH).======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market. He highlights that emphasis is placed on high-quality companies with strong balance sheets. He then goes over his stock picks: Barrick Gold (GOLD), Estee Lauder (EL), and AbbVie (ABBV).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Think every stock is selling off right now on tariff fears? Zacks Stock Strategist, Tracey Ryniec, shares a group of stocks bucking the trend.  (0:30) - Finding Strong Stocks Amid A Stock Market Sell-Off (5:00) - Top Stock Picks To Keep On Your Watchlist Right Now (23:10) - Episode Roundup: BRKB, AON, ABBV

A fresh IPO, outgoing CEO, and Domino's finally joining the field on stuffed-crust pizza. (00:21) Bill Barker and Dylan Lewis discuss: - Mixue's splashy debut on the Hong Kong stock exchange, and how the boba tea chain stacks up to Starbucks and McDonald's. - Rodney McMullen's departure from Kroger and what's next for the nation's largest grocery chain. - Domino's finally delivering what the people want: stuffed crust pizza. (17:41) Have you seen a med spa in your neighborhood? Mary Long caught up with analyst Nick Sciple to find out why this industry is booming and one company that's selling a few products that can help you look a little younger. Article discussed: https://www.bloomberg.com/news/articles/2025-02-19/med-spas-boom-with-botox-lip-filler-weight-loss-drugs-in-demand Companies discussed: LKNCY, KR, DPZ, PZZA, ABBV, EOLS Host: Dylan Lewis Guests: Bill Barker, Nick Sciple, Mary Long Producer: Mary Long Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio, desglosamos los eventos más relevantes que están impactando los mercados y la tecnología: Mercados atentos a aranceles y datos económicos: El $SPX, Nasdaq 100 y Dow operan estables mientras los inversionistas siguen la incertidumbre sobre los aranceles de Trump a México y Canadá. Además, analizamos el impacto de los próximos datos del PMI e ISM Manufacturing. Bitcoin se dispara por respaldo de Trump: $BTC-USD supera los $95K tras el anuncio de la Crypto Strategic Reserve y la primera Crypto Summit en la Casa Blanca. Evaluamos cómo esto afecta al mercado cripto y qué esperar en el sector. Boston Scientific adquiere SoniVie: $BSX pagará hasta $540M por una nueva terapia de hipertensión. Analizamos cómo esta compra refuerza su portafolio y qué impacto tendrá en su crecimiento. Honor apuesta por la IA: La compañía china invertirá más de $10B en IA en los próximos cinco años, presentando su estrategia en el MWC de Barcelona. Discutimos cómo esto posiciona a Honor en la competencia global de inteligencia artificial. AbbVie entra en el mercado de la obesidad: $ABBV firma un acuerdo con Gubra por hasta $2.2B para desarrollar un tratamiento experimental contra la obesidad. Evaluamos el impacto de esta inversión en el creciente sector farmacéutico. Acompáñanos para analizar cómo estos eventos están transformando los mercados financieros, la tecnología y la biotecnología. ¡Un episodio cargado de información clave!

Today's Big 3 focuses on companies that couldn't be more different, but Prosper Trading Academy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's watching in AbbVie (ABBV), Electronic Arts (EA), and Constellation Energy (CEG). Rick Ducat turns to the technicals behind all three companies and points out the areas investors should watch.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Motley Fool Senior Analysts Matt Argersinger and Anthony Schiavone join Mary Long to discuss:  - How a company enters into the Dividend Seven. - If Home Depot can still be a growth stock. - The metrics that dividend investors need to understand.  - Companies that have raised their dividend for decades. Companies discussed: PLD, JPM, PEP, HD, ABBV, MCD, BLK Host: Mary Long Guests: Matt Argersinger, Anthony Schiavone Producer: Ricky Mulvey  Engineers: Desireé Jones, Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

What Abbreviation Do You Use The Most? | The Autumn Wind = Football | Most Common Bday & Mr. Greedy Has Died | DUGY Lines | OttaWHAT? | Helpful Tips For Our Government Friends Going Back To Work | The 7-10 | Invisible Doritos & Nose Lego | DUGY Lady Goes For Jason's Jugular 

Top Food and Healthcare stocks. And more… Includes a 100-company ranking of companies producing the most favorable human life impacts. By Ron Robins, MBA Transcript & Links, Episode 136, August 23, 2024 Hello, Ron Robins here. It's good to be back after my summer break! So, welcome to this podcast episode 136 titled “Top Food and Healthcare stocks. And more…” Presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Now, remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the articles for more company and stock information. ------------------------------------------------------------- 3 Plant-Based Food Stocks That Could Be Multibaggers in the Making: July Edition I'm starting with this article on food stocks as it's a segment that many of you are interested in. It's titled 3 Plant-Based Food Stocks That Could Be Multibaggers in the Making: July Edition. It's by Philippa Main and found on investorplace.com. Now some quotes from the article. “Investors have many reasons for investing in plant-based food stocks… But there are also a lot of ups and downs in the vegan-friendly and plant-based industries. Even one of the most recognizable names in the vegan meat industry, Beyond Meat (NASDAQ:BYND), has been down consistently over the last five years, with very few times of sustained value. However, the overall sector's potential for growth remains robust… The plant-based food market value is currently at $46.7 billion and could expand to $96.6 billion by 2033. That's a compound annual growth rate (CAGR) of 8.4%... 1. Laird Superfood (NYSEAMERICAN:LSF) Specializes in providing plant-based coffee creamers, hydration supplements and other foods. The stock topped out at $57 in 2020 but has since dropped dramatically. It is now trading at around $4 a share. However, recent quarterly results prove that the company is back on the upswing…  The company's 22% net sales growth during the first quarter was among the top results for any company in the food industry. The company saw at least a 40% gross margin. While the company still operates at a net loss, its balance sheet remains strong with no debt. The company raised its outlook for net sales thanks to the positive Q1 results. Laird Superfood stock is affordable for investors looking to enter the vegan-friendly and plant-based food stocks segment. Laird Superfood has many potential growth opportunities on the horizon… It recently received a $32 million influx of funding from WeWork. All this combined means investing now could see great returns in the long term. 2. SunOpta (NASDAQ:STKL) has been producing plant-based food and beverages for over 50 years. In the past three years, the company has committed over $200 million to expanding production capacity and reaching its goal of doubling its plant-based business by 2025. Across the several segments the company operates in, there is a $22 billion addressable market. The company's nutritional beverages sector saw the largest year-over-year (YOY) growth at 20%. The company also partners with other major names in the food retail industry. These include Costco (NASDAQ:COST), Walmart (NYSE:WMT) and Target (NYSE:TGT). Partnering with big retail brands helps increase the exposure of its products and, in turn, generates higher sales volume. SunOpta stock has had its ups and downs over the past five years but currently has a 93% upside. 3. Tyson Foods (NYSE:TSN) One of the most well-known chicken brands in the U.S. may not seem like a good pick for a list of plant-based food stocks. For investors who want to feel good about investing in companies working toward making more plant-based options but don't want to gamble on a company solely focused on that sector, Tyson Foods is a good way to diversify.  Though down substantially over the last five years, Tyson Foods stock has seen a rally of 10% in the last 12 months and 6.5% year-to-date (YTD). In the previous five years, Tyson has been increasing its plant-based offerings through its brand, Raised and Rooted, and has 10 plant-based products. These include plant-based patties, ground meat substitutes, sausages and nuggets. As inflation dampens demand for meat as prices soar, Tyson's presence in the plant-based industry will give it a head start compared to its competitors.  Though there have been some financial troubles for the company in the last year or so, things are starting to turn around.” End quotes. ------------------------------------------------------------- The energy transition from fossil fuels will power these stocks - including Big Oil Now, this next article acknowledges the energy transition, however, some of the comments and companies suggested will not appeal to many ethical and sustainable investors. I wondered long and hard as to include this article or not. However, since the European Commission is likely to include natural gas in its preferred funding energy financing initiative, I ‘dared' to include it. The article is titled The energy transition from fossil fuels will power these stocks - including Big Oil. It's by Jakob Wilhelmus, provided by Dow Jones, and found on morningstar.com. Here are some quotes. “Modernizing the grid The International Energy Agency estimates that to power itself primarily with renewable energy, the world would need to add or replace nearly 50 million miles of transmission lines by 2040… For investors, that creates opportunity around the complementary infrastructure that is needed to build out the grid. Companies such as Eaton (ETN) that provide essential components - including inverters or substations for transmission lines - are well-positioned to take advantage of these ambitious goals. Their central role in the energy transition over coming years may not be fully appreciated today, but markets might soon catch up. Shifting to the greener end of fossil fuels Fossil fuels will certainly continue to be a component of the energy system of the future…  Indeed, global demand for liquified natural gas (LNG) is expected to grow by more than 50% by 2040 as the coal-to-gas transition expands in China and South Asia… For investors, it is critical to seek energy-sector companies that are forward-looking and are finding ways to remain energy providers regardless of what the primary energy sources might be. Two such companies are TotalEnergies (TTE) and Shell (SHEL), which are expanding natural-gas production and transport capabilities. Pipelines are another way to take advantage of the global shift to natural gas. Often these firms have long-term purchase agreements in place, providing investors with an attractive ‘toll collection' that provides a differentiated risk-return proposition in the natural-gas space: exposure to booming demand with less exposure to short-term price volatility. These characteristics and accompanying cash flows make major pipeline players including Enbridge (ENB) and Kinder Morgan (KMI) particularly interesting for debt investors. Getting smart on energy use Investors should also pay close attention to innovation around managing demand and using energy supplies more efficiently… This has created a two-way system, where customers actively manage their energy consumption through smart appliances or storage, while system operators have increased capabilities to manage electricity distribution and generation. This development might benefit companies, such as Schneider Electric (SBGSY), that provide smart sensors and devices all the way to the software that allows grid operators to optimize supply and demand… Global renewable capacity grew by 50% in 2023 and these sources offer some of the lowest cost of producing electricity today. But even this pace of growth in renewables may not be enough to account for the steep rise in energy demand.” End quotes. ------------------------------------------------------------- The 3 Best Healthcare Stocks to Buy in August 2024 Now, here's an article on another favorite sector, healthcare, and it's titled The 3 Best Healthcare Stocks to Buy in August 2024. It's by investorplace.com and was seen on markets.businessinsider.com. Here are some interesting quotes. “The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027. 1. Bristol-Myers Squibb (NYSE:BMY). The pharmaceutical powerhouse consistently ranks as one of the top companies on the market, and has several drugs that generate billions of dollars in revenue. Furthermore, Bristol-Myers Squibb has a number of drugs currently in clinical trials that could bring in huge success over the next decade. Among these is schizophrenia treatment Eliquis KarXT. The drug is expected to receive a recommendation from the FDA as early as next month. If it gets approved, it will be the first newly developed treatment for schizophrenia. That is a market that is estimated to grow to more than $7 billion in just four years. Right now, the stock is down over 10% this year alone and 20% year-over-year. Investors should buy while the stock is down.  2. AMN Healthcare Services (NYSE:AMN) is a medical care facilities company. It supplies healthcare workers, including nurses and industry professionals, on a temporary basis. It experienced huge success from high healthcare worker demand when there was a worker shortage. For those investors who are looking for high-risk, high-reward healthcare stocks, AMN should be on their radar. The company's recent earnings reports look very promising. In Q2 2024, AMN reported earnings per share (EPS) of 98 cents, beating analyst's estimates by almost 20 cents. This was the fourth consecutive quarter that AMN Healthcare Services beat the earnings estimate. Furthermore, AMN trades at 13.64 times forward price to earnings ratio, which is lower than the majority of its competitors in the market. Before it bounces back to its peak price from 2022, investors should buy the stock. 3. Rapport Therapeutics (NASDAQ:RAPP), a biotech company that is backed by Johnson & Johnson (NYSE:JNJ). The company went public on June 7th of this year, and it raised $154 million in initial public offering. The stock price ended up to over $20 on the first day it went public, and as of writing, it goes for $19.05. While there is still lots to learn about the company as it is new to the market, there are certainly things that will attract many investors.  Rapport Therapists is currently developing a focal epilepsy drug. The phase two trials should begin in the next few months, which means that there is going to be exciting news for the biotech startup for the upcoming years. This is especially exciting considering that in the U.S. alone, there are more than three million adult epilepsy patients, which means that it is a sizable market with room to explore.” End quotes. ------------------------------------------------------------- The 2024 Humankind 100 List This next article is a company ranking I watch every year as its methodology is fascinating. It's the Humankind 100 List and the 2024 edition has just been published. I found it on businesswire.com. Here are some quotes. “As the challenges of creating transparency around Environmental, Social and Governance (ESG) data and rankings become increasingly apparent, Humankind developed a holistic, quantitative way to calculate impact in terms of human benefit versus human suffering… This year, Alphabet (GOOGL)… scored highest in the ranking. The positive value of creating free digital tools for consumers outweighs the negative impact of factors like data harvesting in Humankind's analysis. Other companies rounding out the top 10 include: Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Merck & Co. (MRK), Procter & Gamble (PG), Pfizer (PFE), Amgen (AMGN), Microsoft Corp (MSFT), and Bristol-Myers Squibb (BMY). The complete rankings… can be found at rankings.humankind.co.” End quotes. ------------------------------------------------------------- Finally, here's one other article that will interest some of you. It's titled Bank of New York Mellon a Top Socially Responsible Dividend Stock With 2.9% Yield. It's by BNK Invest and found on Nasdaq.com. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips for this podcast titled: “Top Food and Healthcare stocks. And more…” Please click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these troubled times! Contact me if you have any questions. Thank you for listening. Now my next podcast will be September 6th. I'll talk to you then! Bye for now.   © 2023 Ron Robins, Investing for the Soul  

Dr. Shaalan Beg and Dr.Mohamed Salem discuss key abstracts that will be presented at the 2024 ASCO Annual Meeting, including hypoxia-response CAR T- cell therapy for solid tumors, GPC3-specific CAR T- cell therapy in hepatocellular carcinoma, and the promising efficacy of targeted therapies in GI cancers.  TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I am Dr. Shaalan Beg, your guest host of the podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Cancer Center. In today's episode, we'll be discussing some key abstracts in GI cancers that will be presented at the 2024 ASCO Annual Meeting. I'm delighted to welcome Dr. Mohammed Salem, a GI medical oncologist at the Levine Cancer Institute at Atrium Health, for this discussion. Our full disclosures are available in the transcript of this episode. Mohammed, it's great to have you back on the podcast. Dr. Mohamed Salem: Thank you, Dr. Beg. It's always a pleasure to be here. Thanks for having me.  Dr. Shaalan Beg: So we're seeing more and more exciting data emerge on the role of ctDNA in GI cancers. And that's a topic that we've covered fairly extensively on the podcast. This year, in Abstract 3513, investigators used a novel, highly sensitive HPV ctDNA assay to evaluate the clinical outcomes of HPV ctDNA status in people with localized anal cancer treated with chemoradiation. And we know that prior HPV infection is associated with 90% of anal cancers. Can you give us a summary of the study and why it's so important to the clinical care we're giving our patients today?  Dr. Mohamed Salem: Sure. So, as you already alluded to, in the current era of precision oncology or precision medicine in general, there is an effort to try to maximize treatment efficacy and minimize the side effects. We're trying to understand how to do that by developing more biomarkers. I think this was a very interesting study that was led by Dr. Morris of MD Anderson. As you mentioned, he tried to determine the correlation between that circulating tumor DNA at different timelines and also associated that with the relapse. Obviously, as we all know, HPV infection is linked to about over 90% of anal cancers, and anal cancer is increasingly common in the U.S.  The study design includes patients from stage 1, 2, and 3 anal cancer treated with curative intent concurrent chemo radiation and the plot sample to collect circulating DNA was taken at five weeks of treatment and then at various intervals, including 3months, 6  months, 9 months and 12 months, to detect the HPV circulating DNA. And the analysis was done to correlate detection of circulating DNA with a relapse.  So what they observed is after collecting the samples at the end of the treatment, which is 5 weeks, followed by 3 months, 6 months, 9 months, and 12 months following treatment using the correlation between the detection of circulating tumor DNA as well as the recurrence rate, they were able to identify that about 22% was seen at 5 weeks, 13% was seen at three months, then 10% was seen at 6 months, and 0% actually was seen at 12 months. In the final analysis, they concluded that detection of circulating DNA at 3 months was significantly associated with a relapse rate of those patients. And also, they looked at the baseline stage, T stage, end stage, age and other perhaps prognostic factors. But the clinical implication of that trial is this finding supports the potential of integrating now the circulating DNA analysis and routine post-treatment surveillance, which hopefully will help us identify those patients with high risk of relapse and whether they can be treated with adjuvant therapy  in context-free drug trial or even like more close surveillance. Obviously, this is a very novel study, so it needs validation. Also, we need to understand more about the platform used because with the immersion technology and how fast this field is moving, I think it's important to look at this platform or other platforms. I think as a concept it's very interesting and hopefully will help us to identify patients with higher risk. So, I'm looking forward to hearing the full presentation. Dr. Shaalan Beg: Moving on to colorectal cancer, Abstract 3514 is a trial of hypoxia-responsive CEA CAR T-cell therapy for people with heavily pretreated solid tumors where this was administered intraperitoneally or intravenously. And you know, as a solid tumor oncologist or GI oncologist, we've been watching the hematologic space evolve so dramatically in the last five years with cellular therapies that it's exciting to see these CAR T-cell approaches being applied in solid tumors with some results. So can you talk about this study and whether you think it will influence clinical practice?  Dr. Mohamed Salem: Of course, I'm actually very excited to see this study because as you mentioned, CAR T-cell therapy has been utilized in hematological malignancies for the last several years and in fact it's becoming a center of care. As you know, it's very effective in certain tumors. Unfortunately, we did not see a similar result in solid tumors thus far. I know we are trying to make progress, but we are definitely not seeing the same efficacy in solid tumors. And also, of course, in CRC and many other tumors, we need more target options, so I was very excited to see this abstract. And I want to give a little bit of background why this abstract is important. Many solid tumors have a low oxygen level environment, hypoxia obviously, which can impact the effectiveness of CAR T therapy. So hypoxia can suppress the immune response, leading to poor performance of the immune cells like the T cell within the tumor. The investigators, to overcome that challenge, meaning hypoxia impacting the efficacy of the T cell, they were actually able to engineer a CAR T cell to be hypoxia responsive. And what does that mean? That the cells are designed to become more active in low oxygen conditions, which is more difficult in many of the solid tumors. The reason that's very interesting is because, one, it reduces exhaustion of the T cell, meaning like when you have the T cell active all the time, they get exhausted. So when you have the T cell in the resting state, until they reach the tumor environment and they get activated by the hypoxia status, now you reduce the expulsion of the T cell. But also that one overcomes the resistance. So once activated in the tumor hypoxic environment, this CAR T cell shows increased efficacy in targeting and killing the cancer cell.  Based on that concept, the investigators conducted a phase 1 dose escalation study in solid tumors. So this was a phase 1 open label group escalation study involving patients with tumor suppressed CEA and also had relapsed refractory second line treatment. The trial actually included 2 routes of administration, which I think was very interesting – IV versus intraperitoneal, IP, way of administration. And they enrolled about 40 patients between June of 2022 and January 2023. And 35 patients had colorectal cancer, 3 patients had gastric cancer, and 2 patients had non-small cell lung cancer. Overall, there was no surprising safety data. In terms of side effects, it was largely macrocystis, colitis. Unfortunately, they had 1 treatment that did not finish. But the interesting feature was the efficacy of that concept was demonstrated and in fact they were able to see more disease response and control at this rate with IP infusion, which I think is a very novel approach. I would look forward to trying and looking into this kind of delivery, especially in CRC and other tumors. Dr. Shaalan Beg: Because we've known that historically managing disease intraperitoneally has been challenging with cytotoxic chemotherapies and even surgical approaches that have been deployed can be fairly morbid as well. So looking at novel delivery mechanisms can help us understand, maybe be able to manage side effects of treatments in different ways and open doors for treatment in diseases that otherwise we couldn't manage. So definitely a very novel and exciting approach on this study.  Dr. Mohamed Salem: I agree. I think the idea of administering an IP route is a very interesting idea.   Well, Shaalan, there is another study in CRC, Abstract 3515. This is the first human study of ABBV-400, cMET–targeting antibody-drug conjugate in advanced solid tumors. Can you tell us about this promising data? Dr. Shaalan Beg: Yeah, so we've known that cMET is a very relevant biomarker across many cancers, particularly colorectal cancer, and it is overexpressed in a fairly large proportion of multiple diseases. But there hasn't been an effective regimen that has been found to be tolerable to target this specific biomarker. In this study, the investigators are evaluating an antibody drug conjugate, which takes the cMET targeting antibody telisotuzumab and conjugates it to a novel topoisomerase one inhibitor payload. And there's a phase one study that enrolled people across multiple different tumor types. This was presented at ASCO 2023. And this year, the investigators are coming in and giving the results of a colorectal cancer cohort within that study. Patients were enrolled in the dose escalation phase, and in the dose expansion phase, there were 122 colorectal cancer cases; so a fairly healthy size colorectal cancer population. And the median number of prior lines of therapy was 4, which is fairly consistent with what we would expect in our clinical population for people with colorectal cancer. So what they found in terms of efficacy is that the response rates, the confirmed overall response rates, were between 15 and 20%, depending on what dose of the medication the patients had received. They enrolled people regardless of cMET expression and then evaluated the response based on a higher or lower cMET expression. And those with higher cMET expression had an overall response rate of >30%, while those with lower cMET expression had a response rate of 10 to 15%. So they still had a response rate, which for fifth-line colorectal cancer is something to be aware of and it could be a marker of more significant clinical activity than other treatments that are out there.  And with the antibody drug conjugates, it's also important for us to keep an eye on the side effect profiles because a lot of these agents can have distinct side effect profiles that otherwise we wouldn't be familiar with. And in this study, 64% of participants had a grade 3 or above treatment emergent adverse events, and 41% had serious adverse events. So definitely something to think about. And most of these were hematologic toxicities, 30% had grade 3 or worse anemia. Neutropenia was seen, in grade three and above, was seen in 25%, leukopenia or grade three and above was seen in 12%, and thrombocytopenia again around 12%. And the non-hematologic toxicities were nausea, fatigue, vomiting and diarrhea. There was some interstitial lung disease, pneumonitis, which was seen in 7% of the total population, of which 2% had grade three or above. So definitely something to think about. From my perspective, I really am excited about this presentation because we're seeing evidence of clinical activity focused on cMET for refractory colorectal cancer compared to other agents that are out in the market. If this pans out in future studies, it could definitely change the way we deliver our treatments. Dr. Mohamed Salem: I totally agree that we actually need more therapy for those patients. And I'm not surprised that the myelosuppression, as you mentioned, was in fifth-line treatment. So this patient had large exposure to cytotoxic agents before.   So, looking at CAR T once more, there is a very interesting Abstract 4019, which is a study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR T, in patients with advanced hepatocellular carcinoma (HCC). What are your key takeaways from this study, Shaalan? Dr. Shaalan Beg: This is a first-in-human study. It enrolled people with advanced HCC who failed on one or more lines of prior therapy and they were given one single infusion of C-CAR031 after standard lymphodepletion and they enrolled 24 patients across 4 dose levels. If we look at the overall response rate, 50% of the 22 people who were eligible for response assessments had a partial response. This response rate varies based on the dose level itself and the investigators claim a 90% disease control rate. So definitely when we think about standard treatments for hepatocellular cancer after first line therapy, this is something which will catch a lot of people's attention. Again, with CAR T-cell therapy, we need to be aware of the risk of potential toxicities. There were no dose limiting toxicities and CRS or cytokine release syndrome was observed in 91% of patients, while a very small proportion, about less than 5%, had grade three CRS. Most of the side effects here were, again, lymphocytopenia, neutropenia, thrombocytopenia, and some transaminitis in 16% of patients. They did see tumor reduction in 90%, not only in the intrahepatic disease, but also in the extrahepatic disease. And again, these are people who had BCLC stage C disease. So this included people with hepatic and extrahepatic metastases. And in terms of prior lines of therapy, 96% of patients had either received immune checkpoint inhibitors and TKIs.  If we think about how some other immune therapy regimens are being developed in the GI cancer space, there is some indication that liver lesions may respond differently compared to extra hepatic disease. So in this case, they saw responses in both scenarios, which makes it very exciting, because even though we've seen many approvals of TKIs and immunotherapy, anti-androgenic therapy in hepatocellular cancer, the treatment of these patients is still extremely difficult because of their underlying hepatic dysfunction. And it'll be very interesting to see how this treatment unfolds.  Dr. Mohamed Salem: You summarized it very well, Shaalan. I echo your thoughts. What is also interesting about that study, it's actually targeted at the GPC strain, which is prevalent in HCC but not normal tissue, which goes back to your comment about the toxicity, and hopefully we can also manage treatment in the context of underlying liver disease.  Dr. Shaalan Beg: I guess it's fair to say that we're both very excited to see what's ahead in GI cancers at the Annual Meeting.   Mohamed, thanks as always for sharing your great insights with us on the ASCO Daily News Podcast.  Dr. Mohamed Salem: Thank you all for having me, and I'm looking forward to meeting you and all our colleagues in Chicago in a couple of weeks. Dr. Shaalan Beg: And thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcripts of this episode. I'll be back to cover late breaking abstracts and other key advances in GI oncology after the annual meeting, so please join me for more key insights from ASCO24 and on the ASCO Daily News Podcast. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. Shaalan Beg  @ShaalanBeg  Dr. Mohamed Salem  @SalemGIOncDoc    Follow ASCO on social media:  @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Shaalan Beg:  Consulting or Advisory Role: Ispen, Cancer Commons, Foundation Medicine, Genmab/Seagen  Speakers' Bureau: Sirtex  Research Funding (An Immediate Family Member): ImmuneSensor Therapeutics  Research Funding (Institution): Bristol-Myers Squibb, Tolero Pharmaceuticals, Delfi Diagnostics, Merck, Merck Serono, AstraZeneca/MedImmune    Dr. Mohamed Salem: Consulting or Advisory Role: Taiho Pharmaceutical, Exelixis, Bristol-Myers Squibb, Exelixis, QED Therapeutics, Novartis, Pfizer, Daiichi Sankyo/Astra Zeneca  Speakers' Bureau: Genentech/Roche, Taiho Pharmaceutical, Daiichi Sankyo/Astra Zeneca, BMS, Merck 

In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis. Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos! -

@AviNMash @JoeySolitro @StockSavvyShay are back for Episode 96 after Avo Locks nailed $NFLX buy on last weeks episode (Joey props too for the Buy hat tip)  Underdog Pickem's - 1 minute who we like this week in the NFL  Recap and New Buy | Sell | Hold  Tesla | Align Technology |  TransMedics Group | Netflix  EARNINGS PREVIEW:  Meta | Microsoft | Spotify | Snapchat | Amazon  Monday: $CDNA, $LOGI, $CLF, $WHRTuesday: $KO, $VZ, $GE, $GM, $SPOT, $MSFT, $V, $SNAP, $TXN, $TDOCWednesday: $TMUS, $BA, $ADP, $CZOO, $META, $IBM, $NOW, $ALGN, $MAT, $QS, $PIThursday: $MA, $MRK, $CMCSA, $UPS, $LUV, $MBLY, $OPRA, $AMZN, $INTC, $CMG, $F, $ENPH, $LHX, $DXCMFriday: $XOM, $CVX, $ABBV, $SNY, $CHTR, $TROWCHECK OUT SPECIAL PROMOTIONS FOR OUR LISTENERS: Exclusive UNDERDOG FANTASY SPORTS Get up to Bonus Match instantly (Up to $500) and win up to $3M in their BestBall Mania + $15M In total Prizes.  Promo Code: PTT Signup Link: https://play.underdogfantasy.com/p-pounding-the-table Interested in Automated Trading Bots?  Peakbot is our favorite automated trading bots; great for non experts to leverage covered calls. PeakBot (www.UsePeakBot.com)Promo code: PTTWant to Contact Us?  Email us at Hosts@PoundingTheTablePodcast.comLegal Disclaimer:The thoughts and opinions expressed on this podcast, are solely for entertainment purposes and should not be construed as investment advice. The content provided is based on personal experiences, analysis, and general knowledge about stocks and the financial market.The information shared on this podcast is not intended to be a substitute for professional financial advice. Listeners should always consult with a qualified financial advisor or professional before making any investment decisions. Investing in stocks and other financial instruments carries inherent risks, and individuals should carefully consider their own financial situation, risk tolerance, and investment goals before engaging in any investment activities.The hosts and guests on this podcast are not licensed financial advisors or professionals. They are sharing their personal opinions and experiences, which may not be suitable for everyone. The accuracy, completeness, and timeliness of the information presented cannot be guaranteed, as the stock market and investment landscape are subject to constant changes.Any actions taken based on the content of this podcast are done at the listener's own risk. The podcast hosts, guests, and producers assume no responsibility or liability for any investment decisions, losses, or damages incurred as a result of the information provided on the podcast.

In this video, we'll perform an ABBV stock analysis and figure out what AbbVie looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for AbbVie. And answer is AbbVie one of the best stocks to buy at the current price? Find out in the video above! Global Value's AbbVie stock analysis. TIKR is the website I use for all financial data in my videos. Join me and thousands of investors worldwide by using TIKR to supercharge your investment analysis. All funds from referrals directly support the channel to improve video quality! Referral link - https://www.tikr.com/globalvalue Check out Seeking Alpha Premium and score a 14-day free trial. Plus all funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Discover new investing resources and directly support the channel by shopping my Amazon storefront! All commissions are reinvested to improve the quality of videos! https://www.amazon.com/shop/globalvalue AbbVie ($ABBV) | AbbVie Stock Value Analysis | AbbVie Stock Dividend Analysis | ABBV Dividend Analysis | $ABBV Dividend Analysis | AbbVie Fair Value | ABBV Intrinsic Value | ABBV Fair Value | AbbVie Intrinsic Value | AbbVie Discounted Cash Flow Model | AbbVie DCF Analysis | ABBV Discounted Cash Flow Analysis | ABBV DCF Model #ABBV #AbbVie #ABBVstock #AbbViestock #stockmarket #dividend #stocks #investing #valueinvesting #dividendstocks #dividendkings #investor #valueinvestor #stockanalysis #dividend #dividends (Recorded July 8, 2023) ❖ MUSIC ❖ ♪ "Lift" Artist: Andy Hu License: Creative Commons Attribution 3.0 ➢ https://creativecommons.org/licenses/by/3.0/legalcode ➢ https://www.youtube.com/watch?v=sQCuf...

The Sustainable Stocks The Rich Invest In! Includes the following articles: “10 Sustainable Investing Stocks Billionaires Are Loading Up On”; “The 2023 Humankind 100 Rankings”; “4 ESG Stocks With Net-Zero Emissions Target in the Spotlight”; “What is Renewable Energy? Benefits, Sources, and Top Companies”; “'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch”; and “The Importance Of Sustainable And Impact Investing And 3 Companies That Shine!” Transcript & Links, Episode 111, July 28, 2023 Hello, Ron Robins here. So, welcome to my podcast episode 111 titled “The Sustainable Stocks The Rich Invest In!” It's presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. And look at my newly totally revised website at investingforthesoul.com! Tell me what you think. Now, remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the actual articles for more company and stock information. Also, some companies might be covered more than once and there are also 4 article links below that time didn't allow me to review them here. ------------------------------------------------------------- The Sustainable Stocks The Rich Invest In! I'm beginning with this fascinating article titled 10 Sustainable Investing Stocks Billionaires Are Loading Up On. It's by Ramish Cheema and found on finance.yahoo.com. Here's some of what Mr. Cheema has to say. Note: the number of billionaires quoted is at the end of Q1 2023. Quote. “To compile our list of billionaire sustainable stock picks we first used the Invesco MSCI Sustainable Future ETF (ERTH) and picked out the top forty companies. Then, the number of billionaires that had invested in them as of Q1 2023 was determined and the final list of top ten sustainable stocks according to billionaires is as follows. 10. Ormat Technologies, Inc. (NYSE:ORA) Number of Billionaire Investors: 9 Ormat Technologies is a utility company that focuses primarily on generating power through geothermal sites and solar cells… Out of [24 hedge funds], the firm's largest investor is Ian Simm's Impax Asset Management (IPX.L) with a stake worth $178 million. 9. NextEra Energy Partners, LP (NYSE:NEP) Billionaire Investors: 9 NextEra Energy Partners is an energy company that operates in the natural gas and renewable power industries. The firm announced in May 2023 that it plans to reach Real Zero emissions by 2025 and sell natural gas assets to finance future growth. 8. NIO Inc. (NYSE:NIO) Billionaire Investors: 9 NIO is an electric vehicle manufacturer headquartered in Shanghai, China. It makes and sells both SUVs and sedans and the firm is one of the dominant players in the growing Chinese electric vehicle market. However, a slowdown in the Chinese economy [reduced] vehicle deliveries [by] a sharp 17% annual drop… NIO's largest hedge fund investor [out of 18 hedge funds] is Jim Simons' Renaissance Technologies since it owns ten million shares that are worth $113 million. 7. KB Home (NYSE:KBH) Billionaire Investors: 10 KB Home is an American construction company headquartered in Los Angeles, California. As part of its sustainability push, particularly since construction uses high volumes of timber, the firm announced in July that it will partner up with a nonprofit to fund efforts seeking to preserve landscapes and forest habitats… Among [29 hedge funds], Ken Fisher's Fisher Asset Management is the biggest shareholder with an investment of $110 million. 6. Sunrun Inc. (NASDAQ:RUN) Billionaire Investors: 10 Sunrun is a solar power equipment provider which serves the needs of residential customers in the U.S. by providing products such as panels and energy systems… William B. Gray's Orbis Investment Management is the largest investor [out of 27 hedge funds], courtesy of a $265 million stake that comes via 13 million shares. 5. Meritage Homes Corporation (NYSE:MTH) Billionaire Investors: 10 Meritage Homes Corporation is a construction company that builds different kinds of single family homes in several American states. The firm's shares… are rated Buy on average… The largest [out of 27 hedge funds] is Ken Fisher's Fisher Asset Management with a stake worth $128 million. 4. Darling Ingredients Inc. (NYSE:DAR) Billionaire Investors: 11 Darling Ingredients is a food raw materials firm that focuses its efforts on ensuring that no portion of an animal is wasted during the slaughtering process… [Out of 29 hedge funds] Darling Ingredient's largest investor is Ian Simm's Impax Asset Management since it owns $240 million worth of shares. 3. Enphase Energy, Inc. (NASDAQ:ENPH) Billionaire Investors: 12 Enphase Energy sells solar power products such as microinverters, charging solutions… to residential users… [Out of 55 hedge funds], the biggest shareholder is Jim Simons' Renaissance Technologies through a $198 million investment. 2. First Solar, Inc. (NASDAQ:FSLR) Billionaire Investors: 13 First Solar is an international solar power company that sells products including solar modules to large scale users such as utilities, commercial, and industrial users. Its shares are rated Buy on average… [Out of 39 hedge funds] First Solar's largest investor [is] Jim Simons' Renaissance Technologies with a $312 million stake. 1. Tesla, Inc. (NASDAQ:TSLA) Billionaire Investors: 15 The firm has been facing mixed sentiment from Wall Street in July 2023 after a spectacular stock rally earlier this year. [Out of 82 hedge funds] D. E. Shaw's D E Shaw is the biggest shareholder through its $1.2 billion investment.” End quotes. ------------------------------------------------------------- The 2023 Humankind 100 Rankings The corporate ranking data in this next piece The 2023 Humankind 100 Rankings will be of great interest to most of you. Here's a brief description of what it's about. Quote. “Humankind 100 companies tend to contribute positively to humanity, for example by providing access to food, clean water, healthcare, or free digital services. Meanwhile, companies that hurt people, for example by contributing significantly to climate change or selling toxic products, tend to not make it on to the list.” End quotes. Do have a look at the ranking! The top five companies are Alphabet (GOOG), Microsoft Corp. (MSFT), Eli Lilly & Company (LLY.TI), Johnson & Johnson (JNJ), and Abbvie Inc. (ABBV). ------------------------------------------------------------- 4 ESG Stocks With Net-Zero Emissions Target in the Spotlight Next, we have this article titled 4 ESG Stocks With Net-Zero Emissions Target in the Spotlight. It's by Ritujay Ghosh and found on 247wallst.com. Here's some of what the writer says about their stock picks. “1. Salesforce, Inc. (CRM Quick Quote CRM - Free Report) has successfully attained net-zero residual emissions throughout its value chain. Salesforce has also accomplished its objective of operating solely on 100% renewable energy… Salesforce's expected earnings growth rate for the current year is 42%... Salesforce currently sports a Zacks Rank #1 (Strong Buy). 2. PepsiCo, Inc. (PEP Quick Quote PEP - Free Report) the global beverage giant, is committed to achieving net-zero greenhouse gas emissions by 2040. As part of its sustainability efforts, PepsiCo is actively promoting regenerative agricultural practices… Another key target for PepsiCo is to ensure that all its packaging materials become recyclable, compostable and biodegradable. PepsiCo's expected earnings growth rate for the current year is 9.9%... PepsiCo currently carries a Zacks Rank #2 (Buy). 3. Adobe Inc. (ADBE Quick Quote ADBE - Free Report) aims to attain a zero-carbon operational footprint, emphasizing the development of digital products that have a positive environmental impact. Adobe is actively working toward achieving a 100% renewable energy target by 2035… Adobe's expected earnings growth rate for the current year is 14.5%... Adobe currently sports a Zacks Rank #1. 4. Microsoft Corporation (MSFT Quick Quote MSFT - Free Report) is actively pursuing various initiatives to achieve a net-negative carbon footprint by 2030… Microsoft's expected earnings growth rate for the current year is 4.8%. Shares of Microsoft have gained 23.7% in the past three months. Microsoft currently has a Zacks Rank #3 (Hold).” End quotes. ------------------------------------------------------------- What is Renewable Energy? Benefits, Sources, and Top Companies Now to another new article on renewable energy picks. The article is titled What is Renewable Energy? Benefits, Sources, and Top Companies. It's by Jennifer L. located on carboncredits.com. Now to some quotes from the analyst. “1. General Electric Co. (GE) General Electric has been at the forefront of wind energy technology, consistently enhancing turbine designs and improving efficiency… GE has installed over 49,000 units that generate wind electricity across the globe… GE has also invested in other renewable energy technologies, such as solar power, hydroelectricity, and hybrid. 2. NextEra Energy, Inc. (NEE) Running with a whopping $147 billion market cap, NextEra Energy has been investing billions in developing renewable energy sources. As one of the largest renewable energy producers in the world, the company leads the charge in solar and wind energy production… 3. Iberdrola SA (IBDRY) With a market cap of over $72 billion, Spain-based multinational electric utility company Iberdrola SA has more than 170 years of history. The company is a global leader in the generation, distribution, and trading of clean energy. 4. Orsted A/S (ORSTED.CO) Renewable energy company Orsted A/S excels in developing, building, and operation of offshore wind farms. The Danish firm currently owns the prestigious title of being the world's biggest offshore wind power developer, with a total capacity of over 7.5 GW.” End quotes. ------------------------------------------------------------- 'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch And more on renewable energy with this article 'America is going to lead again': Biden says wind and solar are already 'significantly cheaper' than coal and oil — 3 top US clean energy stocks to watch. It's by Vishesh Raisinghani on finance.yahoo.com. “1. First Solar (NASDAQ:FSLR) First Solar is one of the nation's largest utility-scale solar energy producers. The company's competitive edge stems from its proprietary, advanced thin-film module technology… Investors seeking a high-growth bet in this sector should add FirstSolar to their watchlist. 2. Brookfield Renewable (NYSE:BEP) If you're looking for a less risky and more established player in the renewable energy sector, Brookfield Renewable might be a wise bet. The Canada-based asset manager operates one of the largest green energy portfolios in the world… Brookfield is a dividend juggernaut. The stock offers a dividend yield around 4.6% at the moment. 3. SolarEdge Technologies (NASDAQ:SEDG) SolarEdge has rapidly become one of the most well-known and valuable solar energy firms on the market. The company offers an end-to-end system that generates, stores and manages solar energy from home. Nearly three million homes across the globe were equipped with SolarEdge systems by the end of 2022.” End quotes. ------------------------------------------------------------- The Importance Of Sustainable And Impact Investing And 3 Companies That Shine! And I finish up with this article titled The Importance Of Sustainable And Impact Investing And 3 Companies That Shine! It's by Finance Monthly and published on finance-monthly.com. Now some quotes on their recommendations. “1. ICL Group (NYSE: ICL) ICL Group is global specialty minerals company and one of the largest fertilizer manufacturers in the world. ICL focuses on creating sustainable solutions… includes developing innovative fertilizers to increase crop yields while decreasing environmental impact, recycling industrial by-products into useful resources, which aligns with several UN SDGs… 2. NextEra Energy (NYSE: NEE) NextEra Energy specializes in harnessing wind and solar energy across North America… Beyond renewable energy, they also engage in physical contracts, trading activities, and marketing. Their primary income source is distributing gas and electricity to Florida residents. 3. Republic Services (NYSE: RSG) Republic Services specializes in waste management and recycling. As the second-largest waste management company in the United States, its mission is to produce renewable energy through recycling.” End quotes. ------------------------------------------------------------- Other Honorable Mentions – not in any order. 1) Title: Vegan investments: Are you putting your money where your mouth is? On veganfoodandliving.com. By Phil Davis. 2) Title: Why Fastenal is a Top Socially Responsible Dividend Stock (FAST) on nasdaq.com. By BNK Invest. 3) Title: 12 Best Solar Energy and Battery Stocks To Buy Now on finance.yahoo.com. By Hamna Asim. 4) Title: Revolutionizing the Future: “Emerging Green Technology Stocks” to Watch Now! – CLNV, GEVO, ADN, HYSR found on digitaljournal.com. By The Street Reports. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast titled: “The Sustainable Stocks The Rich Invest In!” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these very troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on August 11th. And, again, please look at my new totally revised website at investingforthesoul.com! Tell me what you think! Bye for now.   © 2023 Ron Robins, Investing for the Soul

Here's what is happening in the markets today, Thursday, July 13th Stocks higher for 4 days in a row S&P stalls at 4500 PPI Data is out - Are producer prices getting better? Jobless Claims lower than expected Delta (DAL) reports earnings and sees a big reversal PLUS: We'll review Markus' ABBV trade to see if he should be worried and look at our Earnings Analysis Tool to find out what to expect with JPM earnings tomorrow. This wraps up today's stock market news. If you enjoyed the "Stock Market Today" episode, make sure to subscribe to this podcast. And for more stock market news, visit our YouTube Channel: https://youtube.com/rockwelltrading2008 #todaysstockmarket #stockmarkettoday #stockmarket

Welcome to this week's edition of the Financial Insider! Here's what we have lined up for you:

3M had a big run-up at the end of the week due to some news regarding a first settlement of at least 10 billion. Is now the time to buy? We do a bit of a deeper dive into those litigations to really understand if the path is clear for 3M's recovery. What's more in this episode: our thoughts about Target and their #GoWokeGoBroke failure. Does this provide an attractive buying opportunity? Last but not least, many listeners questions ranging from our thoughts about stocks like $LOTB, $JNJ, $ABBV, $ROG to our opinion about whether beating the market should be a dividend growth investors goal. Having said that, it's a jam-packed show, and as always, C U on the inside!

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/4876193.  Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/4. Phase 1 trial of fixed-duration cevostamab: https://ashpublications.org/blood/article/140/Supplement%201/4415/4923395. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/

For the News of the Week, we started the show by talking about Germany which has now officially entered into a technical recession. As the biggest market in the EU, the market did not overreact to this news. Was it already priced in? Medtronic ($MDT) released full-year results and EDGI gives a brief rundown on the results. The Share price has dropped to 81.50 USD while the company hiked its dividend by 1.5%. Derek questions the dividend safety of the company.  Dividend Increases: Lowe's Companies hikes dividend by 5% Guess hikes the dividend by 33.3%  LyondellBasell Industries hiked the dividend by 5%. Main Topic In the main topic, both EDGI and Derek give 5 points each around what they wish they knew before starting investing.  Key points include Investing regularly is not easy Have a plan and stick to it You cant borrow conviction Dividend Safety Numbers don't lie. Humans do We finish the show with questions from the community where we talk about tickers such as $SBUX, $LIGHT, $JNJ, $ABBV, $VHYL, $WSM  Links mentioned in the show Ep #9 – How we perform fundamental analysis - Dividend Talk  EP #21 – Why the balance sheet of a company is so important to us - Dividend Talk EP #32 – How to spot a company in decline - Dividend Talk  Would you like to support us? Join us on Facebook: https://www.facebook.com/groups/dividendtalk Or if you are interested in buying a nice t-shirt or hoodie with one of your favorite quotes from the dividend talk podcast?  Then check out our Dividend Talk shop:  https://dividendtalk.myspreadshop.ie/

In this video, we'll perform an ABBV stock analysis and figure out what the company looks like based on the numbers. Is Abbvie Inc one of the best Dividend stocks to buy at the current price? Find out in the video above! Global Value's Abbvie Inc stock analysis. Check out Seeking Alpha Premium and score an annual plan for just $119 - that's 50% off! Plus all funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Abbvie Inc ($ABBV) | Abbvie Inc. Stock Value Analysis | Abbvie Inc Stock Dividend Analysis | ABBV Dividend Analysis | $ABBV Dividend Analysis (Recorded August 1, 2022) ❖ MUSIC ❖ ♪ "Lift" Artist: Andy Hu License: Creative Commons Attribution 3.0. ➢ http://creativecommons.org/licenses/b... ➢ https://www.youtube.com/watch?v=sQCuf... 8 Pillar Analysis Props to Everything Money ➢ https://www.youtube.com/c/EverythingMoney

Welcome back to another episode of dividend talk! In today's show we start with discussing the news of the week, i.e. Disney's ($DIS) intention to reinstate the dividend, but also the Search-AI wars ($MSFT $GOOGL) and a mention of Ingredion ($INGR). We then go on to discuss 6 German dividend stocks as the main theme of today ($BAS $DPW $HEI $HBM $COK $MUV2). Some of these are classic choices but we have also a few relatively small companies in there. Last but not least, we're reviewing someone's portfolio and answer several questions of yours. Tickers mentioned are $ENB, $TROW, $KMI, $ABBV, $TRP, $TLX, $HLAG, $CL, $FRE, $BAYN, $BRK, $ALV, $EIN3. Links referenced in the podcast: Dividend Talk YouTube channel: https://www.youtube.com/@DividendTalk Divided Talk Facebook group: https://www.facebook.com/groups/dividendtalk

It doesn't make sense to just focus on profits when you're a human being with other economic interests, says James Katz. He discusses investing in companies that benefit humanity, He examines the Humankind U.S. Stock ETF (HKND), which recently announced its inaugural "Humankind 100" list. Alphabet (GOOGL) topped the list of companies that sustain human well-being. Some other notable companies listed on the "Humankind 100" list include JNJ, PFE, ABBV, VZ, BMY, MRK, LLY, PG, MSFT. Tune in to find out more about the stock market today.

In this JAM PACKED episode, I recap all the Dividends received, stock buys, TWO dividend stock sales, a MERGER with a special dividend, what's up with INTEL, Twitter questions and Who's Trajan?? Stocks mentioned in this episode - TXN, MCD, AOS, MO, IIPR, LEG, MMM, INTC, NSC, UNP, BTI, PEP, WMT, KR, COST, ACI, PG, JNJ, ABBV, INTC Dapper Dividends newsletter SIGNUP FORM Contact - russ@dapperdividends.com Investopedia - What are covered calls? The Official Dapper Dividends Shop! Russ' YouTube video on TEXAS INSTRUMENTS (TXN) The Economist Guide to Analysing Companies Book affiliate link HERE **SPECIAL SEEKINGALPHA.COM offer - $99 for the annual plan. Use this affiliate link and I'll get a few bucks kicked back my way at no additional cost to you- CLICK HERE! WallStreetSurvivor.com "Is Seeking Alpha Worth It?" Why Does The Stock Market Go Up - By Brian Feroldi - (Probably the easiest investing book for an absolute beginner I've ever read). I highly recommend this book for ALL interested in dividend investing, from beginner to advanced - "The Dividend Millionaire" book (The above links are an affiliation where I will receive a small commission at no additional charge to you.) Check my website out - https://dapperdividends.com/ Follow Russ on Twitter - @Rustyram78 Remember this is not financial advice and it's ultimately your money and your responsibility!

The pros and cons of buying a bunch of blue-chip stocks and holding them for 20+ years. (0:30) - Buy and Never Sell Your Investments (3:45) - Breaking Down The 10 and 20 Year Returns For Stock Market Indexes  (10:15) - Have Any Stocks Outperformed The Indexes? (20:40) - Are Dividend Stocks The Best For Long Term Investing? (26:00) - Episode Roundup: GE, IBM, PFE, ABBV, BMY,  MRK, JNJ, UNH, MCD, SBUX, MSFT Podcast@Zacks.com

Simon discusses the recent ebbing of the stock market rally off the June lows. He suggests a trading range might take over where selectivity, discipline, and a heightened focus on fundamentals, particularly free cash flow generation, will increasingly come into play. He brings on Nick to discuss the key takeaways and impacts from the Inflation Reduction Act. Companies mentioned in this episode include MTK, ABBV, GNRC, AAPL, DHR, AMZN, APTV, NN CVX, XOM, and JNJ.